I like the fundamentals of this company the best out of all the big biotech names. It looks like it's calming down here finally after having been sold off hard with all the other biotech / med companies, and now has consolidated and held above the orange downtrend lines. It keeps putting in higher lows on the weekly chart. This looks like a good place to enter here.
Initial entry will be the break of the 3 tight pattern at 111.50
Add at 114.00 as it breaks the peak .
Add as it breaks to new highs at 123.47 IBD buy point.
It holds a 91 composite rating on IBD, weak A/D rating of D+, everything else looks good on the company.
IBD STOCK CHECKUP®
Enter Stock Symbol/Company
GET STOCK CHECKUP
Gilead Sciences Inc (GILD)
ABOUT GILD: DEVELOPS THERAPEUTICS TO TREAT VIRAL, FUNGAL, RESPIRATORY AND CARDIOVASCULAR DISEASES.
Composite Rating 91
MARKET DIRECTION AND INDUSTRY GROUP FOR GILD
Market in confirmed uptrend
Industry Group Rank (1 to 197) 47
FUNDAMENTAL PERFORMANCE FOR GILD
EPS Due Date 02/01/2016
EPS Rating 97
EPS % Chg (Last Qtr) 75%
Last 3 Qtrs Avg EPS Growth 69%
# Qtrs of EPS Acceleration 1
EPS Est % Chg (Current Qtr) 21%
Last Quarter % Surprise 12.2%
3 Yr EPS Growth Rate 106%
Consecutive Yrs of Annual EPS Growth 4
EPS Est % Chg for Current Year 51%
Sales, Margin, ROE
SMR Rating A
Sales % Chg (Last Qtr) 37%
3 Yr Sales Growth Rate 60%
Annual Pre-Tax Margin 65.0%
Annual ROE 99.4%
Debt/Equity Ratio 77%
TECHNICAL PERFORMANCE FOR GILD
RS Rating 71
% Off 52 Week High -12%
Price vs. 50-Day Moving Average 4%
50-Day Average 11.8 Mil
Market Capitalization $159.3 B
% Change In Funds Owning Stock 2%
Qtrs Of Increasing Fund Ownership 8